Epic Wound Care, a subsidiary of New York-based United EcoEnergy Corp., has signed a three-year sponsorship agreement with the American Diabetes Association in support of the ADA's "Mission to Stop Diabetes®" campaign.
Data from the massive ACCORD study on intensive blood sugar control shows that lowering blood sugar levels in people with longstanding type 2 diabetes to near-normal may delay the appearance of signs that point to damage to nerves, eyes, and kidneys, but does not stop their progression toward it.
Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.¹ In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a sham (placebo-like) procedure which consists of anesthesia and a simulated injection in the eye (p=0.0047). The data were presented at the World Ophthalmology Congress in Berlin by Frank G. Holz, an investigator in the trial and director of the University Eye Hospital at the University of Bonn in Germany.
Early management of type 2 diabetes with an integrated team of specialists, including a dietitian, diabetes educator, endocrinologist, cardiologist, and nephrologist, can significantly reduce the incidence of complications and lower healthcare costs, according to an online survey of more than 300 endocrinologists and family practice physicians. The survey was supported by Boehringer Ingelheim Pharmaceuticals, Inc., with the goal of determining the most common obstacles for physicians in treating type 2 diabetes patients and preventing complications. Sermo, the largest physician only online community, conducted the survey. A significant number of these physicians (44 percent) reveal that 50 percent of their patients develop at least one of the following serious complications: cardiovascular disease, nerve pain, kidney disease, stroke, blindness, or limb amputation.
Most women with gestational diabetes know that taking steps to manage the disease during pregnancy is critical for the health of both mother and child. What many women don't realize is that those steps need to continue even after the baby is born.
Researchers at Loyola University have discovered a group of immune system cells called natural killer T (NKT) cells that slow the wound healing process. Their findings pave the way for potential new treatments to accelerate the healing process in slow-to-heal wounds that can occur in people with autoimmune disorders such as type 1 diabetes.
Four risk factors-all of them preventable-reduce life expectancy among U.S. men by 4.9 years and among U.S. women by 4.1 years, according to a study by the Harvard School of Public Health and the Institute for Health Metrics and Evaluation at the University of Washington. (According to U.N. figures, current U.S. life expectancy is 75.6 years for men and 80.8 years for women.)
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.